We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
VRAX | Virax Biolabs Group Ltd | 2.32 | 1.25 | 116.82% | 67,012,899 |
FRGT | Freight Technologies Inc | 1.16 | 0.53496 | 85.59% | 179,837,996 |
TOIIW | Oncology Institute Inc | 0.0297 | 0.013 | 77.84% | 3,043 |
WISA | WiSA Technologies Inc | 3.19 | 1.12 | 54.11% | 28,986,442 |
FBLG | FibroBiologics Inc | 10.18 | 3.48 | 51.94% | 1,646,155 |
SHOTW | Safety Shot Inc | 0.389 | 0.129 | 49.62% | 497 |
AEMD | Aethlon Medical Inc | 0.6272 | 0.1886 | 43.00% | 81,463,118 |
AONC | American Oncology Network Inc | 3.085 | 0.825 | 36.50% | 1,307,565 |
CLEU | China Liberal Education Holdings Ltd | 1.90 | 0.48 | 33.80% | 8,825,756 |
ONMD | OneMedNet Corporation | 2.10 | 0.50 | 31.25% | 7,210,739 |
REPL | Replimune Group Inc | 7.1111 | 1.55 | 27.90% | 2,895,540 |
WiSA Technologies, Inc. (NASDAQ: WISA), a leading innovator in wireless audio technology for intelligent devices and next-generation home entertainment systems, is pleased to report seeing continued penetration into the $296 billion wireless audio market fueled by interest in its WiSA E software.
Phase 1 Clinical Trials of the Hemopurifier® Designed to Include Patients With Solid Tumors Who Have Stable or Progressive Disease During Anti-PD-1 Monotherapy Treatment, Such as Keytruda® of Opdivo® Interested Clinical Sites Have Initiated Submissions For Ethics Committee Review SAN DIEGO, June 3, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today provided the following update on its planned phase 1 safety, feasibility and dose-finding clinical trials of its Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, ...
No Shareholder Action Required at This TimeWASHINGTON, June 6, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it has received an unsolicited, non-binding indication of interest from Cycle Group Holdings Ltd. ("Cycle Group") to acquire the Company for $8.00 per share in cash.
The offering is comprised of 61,538,461 shares of the Company’s common stock (or pre-funded warrants in lieu of shares of common stock). Each share of common stock or pre-funded warrant will be sold with one Series A Warrant to purchase one share of common stock at an exercise price of $0.22 per share (the “Series A Warrants”) and one Series B Warrant to purchase one share of common stock at an exercise price of $0.22 per share or, pursuant to an alternative cashless exercise option, three shares of common stock at a price of $0.001 per share (the “Series B ...
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 71,191.14 | 113.85 | 0.16% | 1.4T | 3,503,774,495 |
ETH | Ethereum | 3,851.84 | -12.37 | -0.32% | 462.12B | 1,863,263,328 |
BNB | Binance Coin | 701.45 | 2.79 | 0.40% | 111.07B | 425,106,710 |
USDT | Tether USD | 0.9996 | -0.0004 | -0.04% | 97.8B | 224,198,013 |
SOL | Solana | 172.99 | -0.450 | -0.26% | 76.28B | 626,958,921 |
STETH | stETH | 3,850.86 | -11.80 | -0.31% | 37.66B | 4,955,681 |
XRP | Ripple | 0.5275 | 0.0019 | 0.36% | 28.72B | 221,306,220 |
USDC | USD Coin | 1.00 | 0.00 | 0.00% | 28.07B | 920,185,980 |
TONCOIN | Wrapped TON Coin | 7.33 | 0.154879 | 2.16% | 25.44B | 109,187,567 |
DOGE | Dogecoin | 0.16305 | -0.00003 | -0.02% | 23.34B | 188,734,813 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions